Amneal Pharmaceuticals, Inc. (AMRX, Financial) experienced a notable stock increase of 5.03%, reaching $8.14 per share with a trading volume of 475,977 shares. The turnover rate stood at 0.15%, and the stock's amplitude was 5.10%. Recent financial reports showed revenue of $702 million, a net loss of $156,000, and a gross profit of $270 million, with a negative price-to-earnings ratio of -9.46.
Among analysts, 75% recommended buying the stock, while 25% suggested holding. Within the pharmaceutical industry, the sector saw a 0.50% rise. Notable performers included Petros Pharmaceuticals, Inc., Teva Pharmaceuticals, and Procaps Group S.A., with Petros Pharmaceuticals showing significant activity and a 38.13% amplitude.
